Experienced in Malignant Mixed Mullerian Tumor

Dr. Jason J. Luke

Hematology Oncology | Oncology

UPMC

University Of Pittsburgh Physicians

5230 Centre Ave, Suite 509,

Pittsburgh, PA

Clinical Trials:Currently Recruiting for 3 Trials

Experienced in Malignant Mixed Mullerian Tumor

UPMC

University Of Pittsburgh Physicians

5230 Centre Ave, Suite 509,

Pittsburgh, PA

OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Jason Luke is a Hematologist Oncology specialist and an Oncologist in Pittsburgh, Pennsylvania. Dr. Luke is rated as an Experienced provider by MediFind in the treatment of Malignant Mixed Mullerian Tumor. His top areas of expertise are Melanoma, Metastatic Uveal Melanoma, Uveal Melanoma, Melanoma of the Eye, and Liver Embolization.

His clinical research consists of co-authoring 233 peer reviewed articles and participating in 49 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Hematology Oncology

Oncology

Licenses

Internal Medicine in PA

Hospital Affiliations

Magee Womens Hospital Of Upmc Health System

Upmc Presbyterian Shadyside

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance

Find your insuranceClose

Accepted insurance plans:

Aetna

Anthem

Cigna

Gateway Health Plan

INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE SNP
OTHER MEDICARE PART D

Highmark

Humana

HMO
INDEMNITY
POS
PPO

UnitedHealthcare

UPMC

View 3 Less Insurance Carriers -

Locations

UNIVERSITY OF PITTSBURGH PHYSICIANS
5230 Centre Ave, Suite 509, Pittsburgh, PA 15232

Call: 412-623-2458

Other Locations

UNIVERSITY OF PITTSBURGH PHYSICIANS
200 Lothrop St, Muh 4 East, Pittsburgh, PA 15213

Call: 412-383-1370

UNIVERSITY OF PITTSBURGH PHYSICIANS
300 Halket St, Pittsburgh, PA 15213

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

48 Clinical Trials

An Open-Label, Multicenter, Phase 1B/2 Study of RP1 in Solid Organ and Hematopoietic Cell Transplant Recipients With Advanced Cutaneous Malignancies

Enrollment Status: Recruiting

Publish Date: October 31, 2025

Intervention Type: Biological

Study Drug: RP1 Genetically-Modified Herpes Simplex Type 1 Virus

Study Phase: Phase 1/Phase 2

Phase I Study Investigating the Safety of Stereotactic Body Radiotherapy (SBRT) With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma

Enrollment Status: Recruiting

Publish Date: August 01, 2025

Intervention Type: Drug, Radiation

Study Drugs: Nivolumab, BMS-986253

Study Phase: Phase 1

A Phase 1 Study With ABBV-CLS-484 Alone and in Combination in Subjects With Locally Advanced or Metastatic Tumors

Enrollment Status: Recruiting

Publish Date: June 03, 2025

Intervention Type: Drug

Study Drugs: ABBV-CLS-484, Programmed Cell Death-1 (PD-1) Inhibitor

Study Phase: Phase 1

Molecular Analysis for Therapy Choice (MATCH)

Enrollment Status: Active_not_recruiting

Publish Date: November 17, 2025

Intervention Type: Procedure, Drug, Other, Biological

Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib

Study Phase: Phase 2

DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

Enrollment Status: Active_not_recruiting

Publish Date: November 17, 2025

Intervention Type: Procedure, Biological

Study Drugs: Ipilimumab, Nivolumab

Study Phase: Phase 2

A Randomized Phase II Study of Anti-PD1 Antibody [MK-3475 (Pembrolizumab)] Alone Versus Anti-PD1 Antibody Plus Stereotactic Body Radiation Therapy in Advanced Merkel Cell Carcinoma

Enrollment Status: Active_not_recruiting

Publish Date: November 12, 2025

Intervention Type: Biological, Radiation

Study Drug: Pembrolizumab

Study Phase: Phase 2

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma

Enrollment Status: Active_not_recruiting

Publish Date: November 10, 2025

Intervention Type: Other, Procedure, Biological

Study Drugs: Ipilimumab, Pembrolizumab, Recombinant Interferon Alfa-2b

Study Phase: Phase 3

A Phase Ib/II Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab in Advanced Solid Tumors

Enrollment Status: Active_not_recruiting

Publish Date: November 06, 2025

Intervention Type: Drug

Study Drugs: ARRY-614+Nivolumab, ARRY-614+Ipilimumab

Study Phase: Phase 1/Phase 2

A Phase 1 Study of Trametinib in Combination With Radiation Therapy for Brain Metastases

Enrollment Status: Active_not_recruiting

Publish Date: October 23, 2025

Intervention Type: Radiation, Procedure, Other, Drug

Study Drug: Trametinib

Study Phase: Phase 1

A Phase 1/2 Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of Azacitidine in Combination With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors and Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Stage IV Microsatellite-Stable Colorectal Cancer (ECHO-206)

Enrollment Status: Terminated

Publish Date: October 21, 2025

Intervention Type: Drug

Study Phase: Phase 1/Phase 2

A Phase 1, Multi-center, Open Label First-in-Human Study With ABBV-CLS-579 Alone and in Combination in Subjects With Locally Advanced or Metastatic Tumors

Enrollment Status: Completed

Publish Date: September 25, 2025

Intervention Type: Drug

Study Phase: Phase 1

A Phase 1, Open-label, Multiple-ascending Dose Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of KD033 (SAR445710) in Subjects With Metastatic or Locally Advanced Solid Tumors

Enrollment Status: Terminated

Publish Date: September 16, 2025

Intervention Type: Drug

Study Phase: Phase 1

Phase I Dose-Escalating Study of RiMO-301 With Radiation in Advanced Tumors

Enrollment Status: Completed

Publish Date: September 15, 2025

Intervention Type: Drug

Study Phase: Phase 1

An Open-label, Phase 1, Dose-escalation Study to Evaluate the Safety and Preliminary Antitumor Activity of TAK-676 With Pembrolizumab Following Radiation Therapy in the Treatment of Non-small-cell Lung Cancer, Triple-negative Breast Cancer, or Squamous-cell Carcinoma of the Head and Neck That Has Progressed on Checkpoint Inhibitors

Enrollment Status: Completed

Publish Date: September 04, 2025

Intervention Type: Drug, Radiation

Study Drugs: Pembrolizumab, TAK-676

Study Phase: Phase 1

A Phase 1/2, Open-Label, Single-Arm, Dose-Escalation and Dose-Expansion Study of the Safety, Tolerability, Pharmacokinetic, and Antitumor Activity of E-602 as a Single Agent and in Combination With Cemiplimab in Patients With Advanced Cancers

Enrollment Status: Completed

Publish Date: August 20, 2025

Intervention Type: Biological

Study Phase: Phase 1/Phase 2

A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared With Investigator Choice in HLA-A*0201 Positive Patients With Previously Untreated Advanced Uveal Melanoma

Enrollment Status: Active_not_recruiting

Publish Date: August 01, 2025

Intervention Type: Biological, Drug

Study Drugs: IMCgp100, Dacarbazine, Ipilimumab, Pembrolizumab

Study Phase: Phase 2

An Open-label, Dose Escalation, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-676 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced or Metastatic Solid Tumors

Enrollment Status: Active_not_recruiting

Publish Date: June 13, 2025

Intervention Type: Drug

Study Phase: Phase 1/Phase 2

Phase II Study of Pembrolizumab and Ipilimumab Following Initial Anti-PD1/L1 Antibody

Enrollment Status: Active_not_recruiting

Publish Date: June 10, 2025

Intervention Type: Drug

Study Drugs: Pembrolizumab, Ipilimumab

Study Phase: Phase 2

Phase I Study of PD1 Blockade by Pembrolizumab With Stereotactic Body Radiotherapy in Advanced Solid Tumors

Enrollment Status: Active_not_recruiting

Publish Date: June 08, 2025

Intervention Type: Drug, Radiation

Study Phase: Phase 1

A Phase 1, Open-Label, Dose-Escalation, and Dose-Expansion Study to Investigate the Safety, Tolerability, PK, PD, and Efficacy of SRK-181 Alone and in Combination With Anti-PD-(L)1 Antibody Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (DRAGON)

Enrollment Status: Completed

Publish Date: April 29, 2025

Intervention Type: Biological

Study Drugs: SRK-181, Anti-PD-(L)1 Antibody Therapy

Study Phase: Phase 1

A Multicenter, Open-Label, Dose Escalation Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the DNA-PK Inhibitor M3814 in Combination With Avelumab With and Without Palliative Radiotherapy in Participants With Selected Advanced Solid Tumors

Enrollment Status: Completed

Publish Date: April 10, 2025

Intervention Type: Radiation, Drug

Study Phase: Phase 1

A Phase 1, First-in-Human, Open-Label, Dose Escalation and Cohort Expansion Study of MGD019, a Bispecific DART® Protein Binding PD-1 and CTLA-4 in Patients With Unresectable or Metastatic Neoplasms

Enrollment Status: Completed

Publish Date: March 06, 2025

Intervention Type: Biological

Study Drug: MGD019 Bispecific DART Protein Binding PD-1 and CTLA-4

Study Phase: Phase 1

Phase II Study of IDH1 Inhibitor Ivosidenib and Nivolumab in IDH1 Mutant Gliomas and Advanced Solid Tumors

Enrollment Status: Completed

Publish Date: February 27, 2025

Intervention Type: Drug

Study Drug: Ivosidenib and Nivolumab

Study Phase: Phase 2

Phase 1 Study Evaluating Genetically Modified Autologous T Cells Expressing a T-cell Receptor Recognizing a Cancer/Germline Antigen in Patients With Recurrent and/or Refractory Solid Tumors(ACTengine® IMA202-101)

Enrollment Status: Completed

Publish Date: February 04, 2025

Intervention Type: Device, Drug

Study Drug: IMA202

Study Phase: Phase 1

Human Leukocyte Antigen Typing and Tumor Antigen Expression Profiling

Enrollment Status: Completed

Publish Date: February 04, 2025

Enrollment Status: Completed

Publish Date: February 04, 2025

Intervention Type: Diagnostic test, Biological

Study Drugs: IMA201, Fludarabine, Cyclophosphamide

Study Phase: Phase 1

A Phase 1 Study of AGEN2373, an Anti-CD137 Monoclonal Antibody, as Monotherapy and in Combination With AGEN1181, an Fc-Engineered Anti-CTLA-4 Monoclonal Antibody, in Patients With Advanced Cancer

Enrollment Status: Completed

Publish Date: January 13, 2025

Intervention Type: Drug

Study Drugs: AGEN2373, Botensilimab

Study Phase: Phase 1

A Phase Ib/II Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 in Combination With Durvalumab (MEDI4736) or Tremelimumab or the Combination of Durvalumab and Tremelimumab Compared to IMCgp100 Alone in Patients With Advanced Melanoma

Enrollment Status: Withdrawn

Publish Date: July 24, 2024

Intervention Type: Drug

Study Drugs: IMCgp100, Durvalumab, Tremelimumab

Study Phase: Phase 1/Phase 2

A Multi-Center Phase I/II Open Label Study to Evaluate Safety and Efficacy in Participants With Metastatic BRAF-mutant Melanoma Treated With Encorafenib With and Without Binimetinib in Combination With Nivolumab and Low-dose Ipilimumab. (QUAD 01: Quadruple Therapy in Melanoma)

Enrollment Status: Terminated

Publish Date: May 23, 2024

Intervention Type: Drug

Study Drugs: Encorafenib, Nivolumab, Ipilimumab, Binimetinib

Study Phase: Phase 1/Phase 2

A Phase 1, Open-label, Multicenter Study of SYNB1891 Administered by Intratumoral Injection to Patients With Advanced/Metastatic Solid Tumors and Lymphoma Alone and in Combination With Atezolizumab

Enrollment Status: Terminated

Publish Date: May 03, 2024

Intervention Type: Drug

Study Drugs: SYNB1891, Atezolizumab

Study Phase: Phase 1

A Phase 1 Open-Label, Multi-Center First in Human Study of TnMUC1-Targeted Genetically-Modified Chimeric Antigen Receptor T Cells in Patients With Advanced TnMUC1-Positive Solid Tumors and Multiple Myeloma

Enrollment Status: Terminated

Publish Date: January 24, 2024

Intervention Type: Drug, Biological

Study Drugs: CART-TnMUC1, Cyclophosphamide, Fludarabine

Study Phase: Phase 1

A Single-arm, Multi-Center, Open-Label Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment in Patients With Hepatic-Dominant Ocular Melanoma

Enrollment Status: Completed

Publish Date: December 21, 2023

Intervention Type: Combination product

Study Drug: Melphalan/Hepatic Device System

Study Phase: Phase 3

A PHASE 1/1b MULTICENTER STUDY TO EVALUATE THE HUMANIZED ANTI-CD73 ANTIBODY, CPI-006, AS A SINGLE AGENT OR IN COMBINATION WITH CIFORADENANT, WITH PEMBROLIZUMAB, AND WITH CIFORADENANT PLUS PEMBROLIZUMAB IN ADULT SUBJECTS WITH ADVANCED CANCERS

Enrollment Status: Completed

Publish Date: December 21, 2023

Intervention Type: Drug

Study Drugs: CPI-006 Anti-CD73 Antibody, Ciforadenant, Pembrolizumab

Study Phase: Phase 1

A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of MGD013, A Bispecific DART® Protein Binding PD-1 and LAG-3 in Patients With Unresectable or Metastatic Neoplasms

Enrollment Status: Completed

Publish Date: December 21, 2023

Intervention Type: Biological

Study Drugs: MGD013, MGD013+Margetuximab

Study Phase: Phase 1

A Phase 1 Open-Label, Multi-Center Study of PSMA Targeted Genetically Modified Chimeric Antigen Receptor T Cells in Patients With Metastatic Castration Resistant Prostate Cancer

Enrollment Status: Terminated

Publish Date: August 21, 2023

Intervention Type: Drug, Biological

Study Drugs: Cyclophosphamide, Fludarabine, Anakinra, Dual PSMA-Specific/TGFbeta-Resistant CAR-T Cells

Study Phase: Phase 1

A Phase I/II Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Using the Intra-patient Escalation Dosing Regimen in Patients With Advanced Uveal Melanoma

Enrollment Status: Completed

Publish Date: March 21, 2023

Intervention Type: Drug

Study Drug: IMCgp100

Study Phase: Phase 1/Phase 2

A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors

Enrollment Status: Completed

Publish Date: February 21, 2023

Intervention Type: Drug

Study Phase: Phase 1

Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma

Enrollment Status: Completed

Publish Date: August 04, 2022

Intervention Type: Drug, Other

Study Drugs: Cabozantinib S-malate, Dacarbazine, Temozolomide

Study Phase: Phase 2

A Phase Ib, Open Label, Multicenter Study of the Safety and Efficacy of MIW815 (ADU-S100) Administered by Intratumoral Injection With PDR001 to Patients With Advanced/Metastatic Solid Tumors or Lymphomas

Enrollment Status: Terminated

Publish Date: May 03, 2022

Intervention Type: Biological, Drug

Study Phase: Phase 1

A Phase 1a/1b Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers

Enrollment Status: Completed

Publish Date: March 09, 2022

Intervention Type: Biological

Study Phase: Phase 1

A Phase 1, Open-Label, Dose Escalation Study of MGA271 in Combination With Ipilimumab in Patients With Melanoma, Non-Small Cell Lung Cancer, and Other Cancers

Enrollment Status: Completed

Publish Date: February 08, 2022

Intervention Type: Biological

Study Phase: Phase 1

A Phase I, Open Label, Multicenter Study of the Safety and Efficacy of MIW815 (ADU-S100) Administered by Intratumoral Injection to Patients With Advanced/Metastatic Solid Tumors or Lymphomas

Enrollment Status: Terminated

Publish Date: December 30, 2021

Intervention Type: Biological, Drug

Study Phase: Phase 1

A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of Ciforadenant as Single Agent and in Combination With Atezolizumab in Patients With Selected Incurable Cancers

Enrollment Status: Completed

Publish Date: August 30, 2021

Intervention Type: Drug

Study Drugs: Ciforadenant, Ciforadenant+Atezolizumab

Study Phase: Phase 1

A Feasibility Study of Sequential Hepatic Internal Radiation and Systemic Ipilimumab and Nivolumab in Patients With Uveal Melanoma Metastatic to Liver.

Enrollment Status: Unknown

Publish Date: April 19, 2021

Intervention Type: Drug, Device

Study Drugs: Ipilimumab, Nivolumab

Study Phase: Phase 1/Phase 2

A Phase I/Ib Open-label, Multi-center, Dose Escalation Study of GWN323 (Anti-GITR) as a Single Agent and in Combination With PDR001 (Anti-PD-1) in Patients With Advanced Solid Tumors and Lymphomas

Enrollment Status: Completed

Publish Date: February 21, 2021

Intervention Type: Drug

Study Phase: Phase 1

A Phase 2 Study of CDX-011 (Glembatumumab Vedotin) for Metastatic Uveal Melanoma

Enrollment Status: Completed

Publish Date: August 21, 2020

Intervention Type: Other, Drug

Study Phase: Phase 2

A Multicenter Phase II Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) in Patients With Advanced Uveal Melanoma

Enrollment Status: Terminated

Publish Date: September 18, 2019

Intervention Type: Other, Biological

Study Phase: Phase 2

A Phase 2 Study of Glembatumumab Vedotin, an Anti-gpNMB Antibody-drug Conjugate, as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma

Enrollment Status: Terminated

Publish Date: September 06, 2019

Intervention Type: Drug

Study Phase: Phase 2

View 45 Less Clinical Trials

233 Total Publications

Lead-in therapy targeting PD1 and/or LAG3 imposes distinct immune phenotypes in first-line treatment of metastatic melanoma.

Journal: medRxiv : the preprint server for health sciences

Published: November 24, 2025

View All 233 Publications

Similar Doctors

Distinguished in Malignant Mixed Mullerian Tumor

Dr. Madeleine C. Brooks

Oncology

Distinguished in Malignant Mixed Mullerian Tumor

Dr. Madeleine C. Brooks

Oncology

UPMC Magee-Womens Gynecologic Oncology

300 Halket Street,

Pittsburgh, PA

(1.7 miles away)

412-663-6008

Languages Spoken:

English

See accepted insurances

Accepting New Patients

Offers Telehealth

Madeleine Courtney Brooks, MD, MPH, specializes in gynecologic oncology and is certified in gynecologic oncology and obstetrics and gynecology by the American Board of Obstetrics and Gynecology. She practices at UPMC Magee-Womens Gynecologic Oncology and is affiliated with UPMC Presbyterian, UPMC Mercy, UPMC Passavant, UPMC Shadyside, and UPMC Magee-Womens Hospital. Dr. Courtney Brooks completed her medical degree at Washington University School of Medicine in St. Louis, residency at University of Pittsburgh School of Medicine, and fellowship at the University of Virginia School of Medicine. LGBTQIA+ Affirming: This provider has completed training on how to create a safe, comfortable, and welcoming environment for LGBTQIA+ patients. This provider may or may not offer LGBTQIA+ specific medical or surgical care. Please ask when scheduling. Dr. Brooks is rated as a Distinguished provider by MediFind in the treatment of Malignant Mixed Mullerian Tumor. Her top areas of expertise are Vulvar Cancer, Cervical Cancer, Endometrial Cancer, Malignant Mixed Mullerian Tumor, and Hernia Surgery.

Distinguished in Malignant Mixed Mullerian Tumor

Dr. William C. Mcbee

Gynecologic Oncology | Oncology | Obstetrics and Gynecology

Distinguished in Malignant Mixed Mullerian Tumor

Dr. William C. Mcbee

Gynecologic Oncology | Oncology | Obstetrics and Gynecology

Monongalia County General Hospital Company

1200 J D Anderson Dr, Suite 301,

Morgantown, WV

(54.6 miles away)

304-598-1996

Languages Spoken:

English

See accepted insurances

Accepting New Patients

William Mcbee is a Gynecologic Oncologist and an Oncologist in Morgantown, West Virginia. Dr. Mcbee is rated as a Distinguished provider by MediFind in the treatment of Malignant Mixed Mullerian Tumor. His top areas of expertise are Lump in the Abdomen, Endometrial Stromal Sarcoma, Endometrial Cancer, Hernia Surgery, and Oophorectomy. Dr. Mcbee is currently accepting new patients.

Advanced in Malignant Mixed Mullerian Tumor

Dr. Jamie L. Lesnock

Oncology

Advanced in Malignant Mixed Mullerian Tumor

Dr. Jamie L. Lesnock

Oncology

UPMC Magee-Womens Gynecologic Oncology

300 Halket Street,

Pittsburgh, PA

(1.7 miles away)

412-663-6008

Languages Spoken:

English

See accepted insurances

Accepting New Patients

Offers Telehealth

Jamie Lesnock, MD, specializes in gynecologic oncology and is certified in gynecologic oncology and obstetrics and gynecology by the American Board of Obstetrics and Gynecology. She practices at University of Pittsburgh Physicians, Department of Obstetrics and Gynecology and is affiliated with UPMC Mercy, UPMC Presbyterian, UPMC Shadyside, UPMC Magee-Womens Hospital, and UPMC Passavant. She completed her residency at University of Pittsburgh School of Medicine and her medical degree at Vanderbilt University School of Medicine. Dr. Lesnock is rated as a Distinguished provider by MediFind in the treatment of Malignant Mixed Mullerian Tumor. Her top areas of expertise are Endometrial Cancer, Ovarian Cancer, Ovarian Carcinosarcoma, Ureteral Reconstruction, and Tissue Biopsy.

VIEW MORE MALIGNANT MIXED MULLERIAN TUMOR DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Luke's expertise for a condition

ConditionClose